Preventing a first episode of esophageal variceal hemorrhage

Cleveland Clinic Journal of Medicine

Volumn 75, Issue 3, 2008, Pages 235-244

  Khaderi, Saira ^a   Barnes, David ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR;

DECISION TREE; DECOMPRESSION SURGERY; DRUG ANTAGONISM; ESOPHAGOSCOPY; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; LIGATION; LIVER CIRRHOSIS; LIVER VEIN; MORTALITY; PATHOPHYSIOLOGY; PORTAL VEIN BLOOD PRESSURE; REVIEW; RISK FACTOR; SCLEROTHERAPY;

DECISION TREES; DECOMPRESSION, SURGICAL; ESOPHAGEAL AND GASTRIC VARICES; ESOPHAGOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEPATIC VEINS; HUMANS; LIGATION; LIVER CIRRHOSIS; PORTAL PRESSURE; RECEPTORS, ANGIOTENSIN; RISK FACTORS; SCLEROTHERAPY; SEVERITY OF ILLNESS INDEX;

EID: 43049130421     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.3.235     Document Type: Review

References (50)

1. D'Amico G, De Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38:599-612.
2. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997; 11:243-256.
3. Kamath PS. Esophageal variceal bleeding: primary prophylaxis. Clin Gastroenterol Hepatol 2005; 3:90-93.
4. Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117:1222-1228.
5. Morales-Ruiz M, Jimenez W, Perez-Sala D, et al. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996; 24:1481-1486.
6. De Franchis R, Dell'Era A, Iannuzzi F. Diagnosis and treatment of portal hypertension. Dig Liver Dis 2004, 36:787-798.
7. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39:280-282.
8. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5:419-424.
9. Bosch J, Masti R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4:1200-1205.
10. Westaby D, Bilhari DJ, Gimson AE, Crossley IR, Williams R. Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut 1984, 25:121-124.
11. D'Amico G, Pagilaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22:332-354.
12. Ideo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology 1988, 8:6-9.
13. Merkel C, Marin R, Angell P, et al. Gruppo Triveneto per l'lpertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127:476-484.
14. Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6:101-106.
15. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985; 5:97-101.
16. Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32:930-934.
17. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99:1401-1407.
18. Hicken BL, Sharara AI, Abrams GA, Eloubeidi M, Fallon MB, Arguedas MR. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. Aliment Pharmacol Ther 2003; 17:145-153.
19. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997; 92:1081-1091.
20. Grace ND, Groszmann RJ, Garcia-Tsao G, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998; 28:868-880.
21. Feu F, Garcia-Pagán JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346:1056-1059.
22. Abraczinskas DR, Ookubo R, Grace ND, et al. Propranolol for the prevention of first esophageal variceal hemorrhage; a lifetime commitment? Hepatology 2001; 34:1096-1102.
23. Groszmann RJ, Garcia-Tsao G, Bosch J, et al; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353:2254-2261.
24. Garcia-Pagán JC, Bosch J. Pharmacological prevention of variceal bleeding. New developments. Baillier Clin Gastroenterol 1997; 11:271-287.
25. Talwalkar JA, Kamath PS. An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis. Am J Med 2004; 116:759-766.
26. Garcia-Pagan JC, Feu F, Castells A, et al. Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. Hepatology 1994; 19:595-601.
27. Lay CS, Tsai YT, Teg CY, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology 1997; 25:1346-1350.
28. Imperiale TT, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001; 33:802-807.
29. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40:65-72.
30. Lui HF, Stanley AJ, Forrest EH, et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002; 123:735-744.
31. Khuroo MS, Khuroo NS, Farahat KL, Khuroo YS, Sofi AA, Dahab ST. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005; 21:347-361.
32. Jutabha R, Jensen DM, Martin P, Savides T, Han SH, Gornbein J. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005; 128:870-881.
33. Psilopoulos D, Gatanis P, Goulas S, et al. Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol 2005; 17:1111-1117.
34. Lay CS, Tsai YT, Lee FY, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2006; 21:413-419.
35. Sarin SK, Wadhawan M, Agarwal SR, Tyagi P, Sharma BC. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005; 100:797-804.
36. Yuksel O, Koklu S, Arhan M, Yolcu OF, et al. Effects of esophageal variceal eradication on portal hypertensive gastropathy and fundal varices: a retrospective and comparative study. Dig Dis Sci 2006, 51:27-30.
37. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist on portal pressure in cirrhosis, Hepatology 1999; 29:334-339.
38. Schepke M, Werner E, Biecker E, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121:389-395.
39. Gonzalez-Abraldes J, Albillos A, Banares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121:382-388.
40. Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41:386-400.
41. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. N Engl J Med 1991; 324:1779-1784.
42. The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. Hepatology 1991; 14:1016-1024.
43. Escorsell A, Feu F, Bordas JM, et al. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1996; 24:423-429.
44. Hayes PC, Westaby D, Williams R. Effect and mechanism of action of isosorbide-5-mononitrate. Gut 1988; 29:752-755.
45. Angelico M, Carli L, Piat C, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 1993; 104:1460-1465.
46. Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997; 113:1632-1639.
47. Garcia-Pagan JC, Villanueva C, Vila MC, et al. MOVE Group. Mononitrato Varices Esofagicas. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001; 121:908-914.
48. Merkel C, Marin R, Enzo E, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP). Lancet 1996; 348:1677-1681.
49. Garcia-Pagán JC, Morillas R, Banares R, et al, Spanish Variceal Bleeding Study Group. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003; 37:1260-1266.
50. Garcia-Tsao G, Sanyal A, Grace N, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46:922-938.